Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by narmacon Feb 09, 2021 4:55pm
115 Views
Post# 32516872

RE:RE:RE:New Zacks Report - $0.60 USD/Share Price Target

RE:RE:RE:New Zacks Report - $0.60 USD/Share Price Target,,hummm,,,, .60 cents USD,,,,aaaccchhhhh,,,,,,way tooooo loooowww,,,,,,,,,,,,,not sure that most of these groups assessing such plays as we have with BTI get direct access,,,but actually,,from what I have read,,,,,they generally do get invites to sit down with managment,,its a synergy,,,especially those analysts who are considered the prestigous ones ,,some get paid,,some dont,,,,not sure how many of these Nostradamus types turn out to be bang on,,,,not many from what I have seen,,,,thats why there are so many out there,,,,,,,,,reason being for the accuarcy issue,,, they dont have next weeks news paper today either,,,nope,,they dont,,,,,jmo
<< Previous
Bullboard Posts
Next >>